daunorubicin has been researched along with tetrandrine in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chen, B; Cheng, J; Dong, Y; Gao, F; Sheng, M; Wang, T; Zhang, P; Zhou, Y | 1 |
| Hirano, T; Liu, ZL; Oka, K; Onda, K; Tanaka, S | 1 |
| Chen, BA; Cheng, J; Dong, Y; Gao, F; Qian, XJ; Sheng, M; Wang, T; Zhou, Y | 1 |
| Ao, ZF; Chen, BA; Gao, F; Shen, HL; Xia, W; Xu, WL; Zhang, YN | 1 |
| Chen, BA; Chen, J; Ding, JH; Gao, C; Gao, F; Li, J; Sun, XC; Wang, XM; Wu, YN; Xu, WL; Zhu, MS | 1 |
| Bao, W; Chen, B; Cheng, J; Ding, J; Gao, C; Gao, F; Sun, Y; Wang, J; Wang, X; Xia, G; Yin, L; Zhao, G | 1 |
| Bao, W; Chen, BA; Cheng, J; Cui, TY; Ding, JH; Gao, C; Gao, F; Schmitt, A; Schmitt, M; Shan, XY; Xia, GH; Zhong, YJ | 1 |
| Bao, W; Chen, B; Chen, W; Cheng, J; Guo, L; Li, X; Liu, R; Wang, Y; Xia, G; Xu, Y | 1 |
| Chen, S; Hirano, T; Onda, K; Sugiyama, K; Tanaka, S; Wang, X; Wu, H; Xu, W; Yamada, H | 1 |
1 trial(s) available for daunorubicin and tetrandrine
| Article | Year |
|---|---|
Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Cytarabine; Daunorubicin; Etoposide; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Recurrence | 2006 |
10 other study(ies) available for daunorubicin and tetrandrine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[Effect of tetrandrine and droloxifene on the reversion of drug resistance of K562/A02 cell line and induction of apoptosis].
Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylisoquinolines; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; K562 Cells; Tamoxifen; Tumor Cells, Cultured | 2002 |
Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
Topics: Alkaloids; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Daunorubicin; Drug Resistance, Multiple; Flow Cytometry; Humans; Leukemia, T-Cell; Tumor Cells, Cultured | 2003 |
[Study on the relationship between [Ca2+]i and the MDR formation in K562/A02 cells].
Topics: Alkaloids; Benzylisoquinolines; Calcium; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; K562 Cells; Tamoxifen | 2004 |
[Effect of tetrandrine combined with daunorubicin on expressions of P21 and P-gp in K562/A02 cells].
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; K562 Cells | 2009 |
Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol and tetrandrine on the reversion of multidrug resistance in K562/A02 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylisoquinolines; Cell Line, Tumor; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Humans; K562 Cells; Leukemia; Morpholines | 2011 |
[Inducing apoptosis and reversal effect of nilotinib in combination with tetrandrine on multidrug resistance of K562/A02 cell line].
Topics: Apoptosis; bcl-2-Associated X Protein; Benzylisoquinolines; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Inhibitor of Apoptosis Proteins; K562 Cells; Pyrimidines; Survivin | 2011 |
Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.
Topics: Antineoplastic Agents; Benzylisoquinolines; Cell Proliferation; Cell Survival; Daunorubicin; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Liberation; Humans; Hydrophobic and Hydrophilic Interactions; K562 Cells; Lactic Acid; Nanoparticles; Particle Size; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polylysine; Transferrin | 2015 |
Tetrandrine enhances glucocorticoid receptor translocation possibly via inhibition of P-glycoprotein in daunorubicin-resistant human T lymphoblastoid leukemia cells.
Topics: Active Transport, Cell Nucleus; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Benzylisoquinolines; Cell Line, Tumor; Cell Survival; Daunorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Leukemia, T-Cell; Receptors, Glucocorticoid; Signal Transduction | 2020 |